Some chemical reagents, such as anti-inflammatory 5-aminosalicylic acid (5-ASA), corticosteroids, thiopurines, calcineurin inhibitors, a Janus kinase inhibitor (tofacitinib), and immunosuppressive agents (such as the anti-TNF-α monoclonal antibody infliximab and the anti-integrin α4β7 monoclonal antibody vedolizumab), have been widely used in clinical IBD therapy [8]. This evidence concerns the gene TNF and inflammatory bowel disease.